JP5906183B2 - 骨障害を治療するための、および、体重を管理するための化合物および方法 - Google Patents

骨障害を治療するための、および、体重を管理するための化合物および方法 Download PDF

Info

Publication number
JP5906183B2
JP5906183B2 JP2012514171A JP2012514171A JP5906183B2 JP 5906183 B2 JP5906183 B2 JP 5906183B2 JP 2012514171 A JP2012514171 A JP 2012514171A JP 2012514171 A JP2012514171 A JP 2012514171A JP 5906183 B2 JP5906183 B2 JP 5906183B2
Authority
JP
Japan
Prior art keywords
bone
subject
pharmaceutical composition
substitution
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012514171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528887A (ja
JP2012528887A5 (cg-RX-API-DMAC10.html
Inventor
クレモンズ，デイヴィッド・アール
ローゼン，クリフォード・ジェイ
Original Assignee
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
メイン・メディカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル, メイン・メディカル・センター filed Critical ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Publication of JP2012528887A publication Critical patent/JP2012528887A/ja
Publication of JP2012528887A5 publication Critical patent/JP2012528887A5/ja
Application granted granted Critical
Publication of JP5906183B2 publication Critical patent/JP5906183B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012514171A 2009-06-04 2010-06-04 骨障害を治療するための、および、体重を管理するための化合物および方法 Expired - Fee Related JP5906183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18420909P 2009-06-04 2009-06-04
US61/184,209 2009-06-04
PCT/US2010/037390 WO2010141811A2 (en) 2009-06-04 2010-06-04 Compounds and methods for treating bone disorders and controlling weight

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253422A Division JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Publications (3)

Publication Number Publication Date
JP2012528887A JP2012528887A (ja) 2012-11-15
JP2012528887A5 JP2012528887A5 (cg-RX-API-DMAC10.html) 2013-07-25
JP5906183B2 true JP5906183B2 (ja) 2016-04-20

Family

ID=43298544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012514171A Expired - Fee Related JP5906183B2 (ja) 2009-06-04 2010-06-04 骨障害を治療するための、および、体重を管理するための化合物および方法
JP2015253422A Pending JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253422A Pending JP2016106098A (ja) 2009-06-04 2015-12-25 骨障害を治療するための、および、体重を管理するための化合物および方法

Country Status (5)

Country Link
US (1) US9220746B2 (cg-RX-API-DMAC10.html)
EP (1) EP2437768B1 (cg-RX-API-DMAC10.html)
JP (2) JP5906183B2 (cg-RX-API-DMAC10.html)
ES (1) ES2602629T3 (cg-RX-API-DMAC10.html)
WO (1) WO2010141811A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016106098A (ja) * 2009-06-04 2016-06-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 骨障害を治療するための、および、体重を管理するための化合物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183212A1 (en) * 2009-01-08 2010-07-22 Numira Biosciences, Inc. Methods and compositions for imaging cartilage and bone
EP2970387A4 (en) * 2013-03-12 2016-07-27 Univ North Carolina COMPOUNDS AND METHOD FOR THE TREATMENT OF ADIPOSITAS AND WEIGHT CONTROL
BR112019016250A2 (pt) * 2017-02-06 2020-04-14 Alize Pharma Iii Sas peptídeos isolados, uso do peptídeo isolado, método para prevenção ou tratamento de um distúrbio ósseo, método para melhorar a formação óssea, método para inibir a reabsorção óssea, método para induzir a deposição óssea, método para induzir a maturação óssea, método de expandir células tronco ex vivo e composição farmacêutica
CA3100665A1 (en) 2018-05-24 2019-11-28 Amolyt Pharma Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
WO2021011283A1 (en) * 2019-07-12 2021-01-21 Northwestern University Insulin like growth factor binding protein bioactive peptide fragments
CN114634552B (zh) * 2022-04-14 2022-12-13 中国农业大学 一种抗肥胖十三肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU746423B2 (en) * 1997-05-05 2002-05-02 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7504374B2 (en) 2000-10-24 2009-03-17 Warsaw Orthopedic, Inc. Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
WO2006034832A2 (en) 2004-09-27 2006-04-06 Univ Muenchen L Maximilians Use of igfbp-2 in senescence diseases and for the maintenance of organ functions
US20080286287A1 (en) 2005-03-30 2008-11-20 Murdoch Childrens Research Institute Methods and Agents for Modulating Cellular Activity
EP2462946B1 (en) * 2006-08-16 2014-07-09 National Research Council of Canada Method of inhibiting cathepsin activity
WO2009019254A1 (en) * 2007-08-03 2009-02-12 Pharis Biotec Gmbh Igfbp-2 c-terminal fragments and uses thereof
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
EP2437768B1 (en) * 2009-06-04 2016-08-10 The University of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016106098A (ja) * 2009-06-04 2016-06-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 骨障害を治療するための、および、体重を管理するための化合物および方法

Also Published As

Publication number Publication date
ES2602629T3 (es) 2017-02-21
US20120149634A1 (en) 2012-06-14
JP2012528887A (ja) 2012-11-15
EP2437768B1 (en) 2016-08-10
WO2010141811A2 (en) 2010-12-09
EP2437768A4 (en) 2013-03-06
EP2437768A2 (en) 2012-04-11
US9220746B2 (en) 2015-12-29
JP2016106098A (ja) 2016-06-16
WO2010141811A3 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
JP2016106098A (ja) 骨障害を治療するための、および、体重を管理するための化合物および方法
US11612639B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
US20100098739A1 (en) Compositions and methods for modular soft tissue repair
US20100112031A1 (en) Compositions And Methods For Regulating Extracellular Matrix Production In Adipose Derived Cells
US20080213235A1 (en) Adipose Tissue Stem Cells, Perivascular Cells and Pericytes
JP2020506200A (ja) バイオロジカルスキャフォールド、バイオロジカルスキャフォールドを含む製品、及び、その使用方法
US11771803B2 (en) Enhancement of osteogenic potential of bone grafts
JP7308151B2 (ja) ヒトｂｍｐ７タンパク質のバリアント
EP3921029B1 (en) Composition comprising ccl5 for use in treating bone break, bone fracture, bone degeneration and osteoporosis
US11466254B2 (en) Composition containing, as active ingredient, culture of chicken bone marrow-derived osteochondral progenitor cells for promoting osteogenesis or inducing chondrogenic differentiation
US20240181135A1 (en) Biochemical activation of dysfunctional skeletal stem cells for skeletal regeneration
Al-Adlaan et al. The Anti-Inflammatory Role of GPNMB in Post-Traumatic Osteoarthritis
KR20260060365A (ko) 골 및 연골 퇴행의 치료를 위한 뇌 유래 골형성 인자 ccn3의 사용 방법
IP Dependence of Post Natal Osteogenic Differentiation on BMP2: Dissection of Osteogenic Lineage Commitment by Lentivirus BMP2 shRNA ex vivo
Hildreth III The Role of Parathyroid Hormone-related Protein in Skeletal Development and Bone Formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160318

R150 Certificate of patent or registration of utility model

Ref document number: 5906183

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees